STAT

Pioneering surgery makes a prosthetic foot feel like the real thing

It was just the occasional wiggle, but it told doctors the prosthetic foot had seamlessly become part of Jim's body. STAT has been following this groundbreaking experiment for 15 months.…

CAMBRIDGE, Mass. — For hours on end last year, Massachusetts Institute of Technology engineers ran the brain-controlled robotic limb through its paces, testing its capabilities on a series of patients and fine-tuning it like a pit crew preparing a race car for the Indy 500.

They had patients flex the prosthetic foot: toe up, toe down. Toe in, toe out. Walk up a flight of stairs, then back down. But it was after the day’s experiments, when patient Jim Ewing was seated and chatting with the team, that they made their most provocative observation: He fidgeted, pivoting the motorized ankle, unconsciously.

It wasn’t much, just a wiggle now and then, but it provided powerful evidence that the new robotic foot had become a seamless part of Ewing’s body in a way that has never been accomplished before with a prosthetic limb, the scientists reported Wednesday.

“A standard amputee, when they’re wearing their leg, doesn’t do any of that,” Dr. Matthew Carty, a Brigham and Women’s Hospital surgeon and co-author of the paper, told STAT. “But Jim, when he was sitting there talking to us, was fidgeting his

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks